Biofrontera Inc. Closes a $4.2 Million Senior Secured Convertible Note
November 22, 2024 09:10 ET
|
Biofrontera Inc.
WOBURN, Mass., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization...
Biofrontera Inc. Reports Third Quarter and Nine-Month 2024 Financial Results and Provides Business Update
November 13, 2024 17:15 ET
|
Biofrontera Inc.
●Total revenues for the third quarter 2024 were $9.0 million, an increase of 1.5% from Q3 2023. Revenue increase would have been 19% if shipments were not delayed due to Hurricane Milton. ●Total...
$6.97 Billion Photodynamic Therapy Market Outlook, 2024-2032, Featuring Detailed Analysis of Gladerma, Sun Pharmaceutical Industries, Biofrontera, Lumibird, Bausch Health Companies, and More
June 06, 2024 04:22 ET
|
Research and Markets
Dublin, June 06, 2024 (GLOBE NEWSWIRE) -- The "Photodynamic Therapy Market Report by Product Types, Application, End-user, Countries and Company Analysis 2024-2032" report has been added to ...
Global Photodynamic Therapy Devices Market Report 2024: Analysis of Products, Applications, End-users and Regional Dynamics to 2034 Featuring Coherent Corp, Biolitec, & Lumibird Medical Among Other Key Players
March 11, 2024 14:11 ET
|
Research and Markets
Dublin, March 11, 2024 (GLOBE NEWSWIRE) -- The "Global Photodynamic Therapy Devices Market Analysis & Forecast to 2024-2034: Market By Product; By Application; By End-user; and By Region" report...
Global Photodynamic Therapy Market Analysis & Forecast 2024-2034: Innovations in Photodynamic Therapy Devices Propel Growth, with Cancer Treatment and Skin Conditions at the Forefront
November 02, 2023 10:03 ET
|
Research and Markets
Dublin, Nov. 02, 2023 (GLOBE NEWSWIRE) -- The "Global Photodynamic Therapy Market Analysis & Forecast 2024-2034: Market By Product; By Applications; By End-user; and By Region" report has been...
ImPact Biotech Announces Research Collaboration to develop a treatment to arrest Pathologic Myopia using its Padeliporfin minimally invasive platform
August 13, 2023 16:16 ET
|
ImPact Biotech
ImPact Biotech to collaborate with Maastricht University researchers to develop a treatment to arrest the progressive condition Pathologic Myopia, a leading cause of irreversible sight impairment and...
ImPact Biotech receives FDA Clearance for Padeliporfin VTP Phase 1 Clinical Program in Peripheral Lung Cancer
August 04, 2023 10:49 ET
|
ImPact Biotech
Padeliporfin VTP Phase 1 trial in Peripheral Non-Small Cell Lung Cancer to start by end Q4 2023 TEL AVIV, Israel, Aug. 04, 2023 (GLOBE NEWSWIRE) -- ImPact Biotech,...
Revolutionizing Photodynamic Therapy: Industry Trends, Growth Opportunities & Market Insights
July 31, 2023 07:13 ET
|
Research and Markets
Dublin, July 31, 2023 (GLOBE NEWSWIRE) -- The "Photodynamic Therapy Market Analysis to 2030" report has been added to ResearchAndMarkets.com's offering. This cutting-edge report explores the...
Photodynamic Therapy Market to Grow at a CAGR of 13.5% from 2022 to 2031, reaching US$ 15.5 Billion: As per TMR Study
July 17, 2023 15:30 ET
|
Transparency Market Research
Wilmington, Delaware, United States, July 18, 2023 (GLOBE NEWSWIRE) -- The global photodynamic therapy market stood at US$ 4.2 billion in 2021, and the global market is projected to reach US$ 15.5...
ImPact Biotech receives FDA Orphan Drug Designation for Padeliporfin VTP in Pancreatic Cancer
July 05, 2023 09:44 ET
|
ImPact Biotech
Designation confers advantages including marketing exclusivity and tax credits Padeliporfin VTP Phase 1 trial in Pancreatic cancer to start by end Q4 2023 TEL AVIV, Israel, July 05, 2023 (GLOBE...